home All News open_in_new Full Article

90% Early Detection Rate: BioMark's Breakthrough Lung Cancer Test Gets Patents in $1.5B Asian Market

90% Early Detection Rate: BioMark's Breakthrough Lung Cancer Test Gets Patents in $1.5B Asian Market  Stock Titan


today 8 d. ago attach_file Other

8 d. ago 90% Early Detection Rate: BioMark's Breakthrough Lung Cancer Test Gets Patents in $1.5B Asian Market
attach_file Other
9 d. ago Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer
attach_file Other
1 week ago Nuvation Bio Soars As Japan Approves Ibtrozi for Advanced Lung Cancer
attach_file Other
2 w. ago How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer
attach_file Other
2 w. ago Nuvation Bio stock gains as Japan approves IBTROZI for lung cancer
attach_file Other
2 w. ago NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy
attach_file Other
2 w. ago Nuvation Bio Says Japan Approves IBTROZI For ROS1+ Advanced Non
attach_file Other
2 w. ago Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1
attach_file Other
3 w. ago Novocure’s electric fields device approved for treating lung cancer in Japan
attach_file Other
3 w. ago Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non
attach_file Other


ID: 2296532286
Add Watch Country

arrow_drop_down